biotech

Copycat versions of biotech drugs work just as well as the originals and cost a lot less, according to an analysis of studies of the medicines.

The analysis by researchers at Johns Hopkins Bloomberg School of Public Health finds that so-called biosimilars — medications that are meant to mimic, and compete with, complex and expensive biotech drugs — perform as well as the brand-name versions.

The Seattle area biotech and medical device industry is not likely to produce any companies as big as Microsoft or Amazon. But smaller companies, with strange names, keep popping up—like Etubics, Numera, Obenomics, and NanoString.

And, apparently, this sector is adding jobs.

That’s the word at the annual Life Science Innovation Northwest conference, in Seattle this week.